Pane wikiwiki
Two recent capsule programs make the same point from different directions. Lonza's Capsugel® Enprotect® is a ready-to-use enteric capsule built from HPMC and H…
ʻO ka mea i hōʻike maoli ʻia e ka hana hoʻouna hou
Kūʻai nui ʻia ʻo Cyclic Peptide Koi Pept ʻEkolu kumu i hoʻonohonoho i ka ʻoiaʻiʻo, a ʻo kēlā me kēia mea e kū pono i kahi koi bioavailability.

Mālama. ʻO ka ʻO ka ʻaoʻao huahana Capsugel wehewehe i kahi capsule enteric mākaukau e hoʻohana me ka HPMC a me HPMC-AS polymers me kahi pani paʻa Coni-Snap, ka pale ʻana i nā API e pili ana i ka waikawa a me ka ʻae ʻana i ka lawe ʻana i ka ʻōpū. ʻO ke kūpaʻa waika i ʻōlelo ʻia a hiki i ka pH 6.0, a hoʻopau ka capsule i ka pono no ka hoʻopiha piha ʻana. ʻO ia kahi kikoʻī o ka dosage-form: ʻōlelo ʻia kahi i hoʻolālā ʻia ai ka pūpū e ola ai, ʻaʻole ka mea e hana ai i kahi peptide ma hope o ka hoʻokuʻu ʻana.
ʻO nā capsules Bilayer no ka huli ʻana i ka ileal. ʻO ka ʻO ka hōʻuluʻulu ʻike ʻo Capsugel o Millet et al., ʻEpelika Journal of Pharmaceutical Sciences 2026;224:107601, wehewehe i kahi ʻōnaehana hoʻohui i kahi HPMC- a me ka papa o loko e pili ana i ka pullulan me kahi papa ethylcellulose o waho i loaʻa ka sodium alginate ma ke ʻano he pore mua - ka mana diffusion a me ka hana pane ʻana i ke kaiapuni i hoʻokahi ʻano hana.. Ua loiloi ka haʻawina i ke ʻano o ka hoʻopili ʻana i ka haku mele a me nā ʻāpana hana i ka pale ʻana i ka ʻōpū, hikiwawe, ka wehe ʻana a me ka hoʻokuʻu ʻana, a ʻike i nā ʻano alginate kikoʻī a me nā kūlana hoʻōla i hoʻopuka i nā kiʻi hoʻokuʻu lohi e kūlike me ka huli ʻana i ka ileum distal.. He haʻawina kaʻina hana-a-formulation. ʻAʻole ia e hōʻike i ka absorption vivo.

Palena ʻelua papa GLP-1. ʻO ka ʻO ka pepa Frontiers ma kahi hoʻokumu lipid me nā capsules enteric ʻo ia ka peptide kūpono loa o nā ʻekolu. Ua hoʻokumu nā mea kākau i ka GLP-1 analog exenatide ma ke ʻano he hydrophobic ion pair (HIP) i loko o kahi hoʻokumu lipid-based me nā mea hoʻonui hoʻonui permeation, a laila hoʻomohala ʻia nā capsules enteric gelatin/HPMC-AS i hoʻokō i nā koi hoʻokuʻu lohi USP. Mālama ka pūpū capsule i nā maʻi ʻōpū; pale ka lipid droplets mai nā protease ʻōpū. Hōʻike nā mea kākau i ka hopena ma ke ʻano he hōʻike in vitro o ka manaʻo a ʻōlelo maʻalahi i ka vivo pharmacokinetic a me nā haʻawina pharmacodynamic., paʻa lōʻihi, a me ka hana lōʻihi o ka hoʻokumu ʻana-capsule e hana ʻia.
Heluhelu pu, uhi nā kumu ʻekolu i ʻekolu papa like ʻole o ka pilikia hoʻokahi - pūpū, matrix, a me ka peptide-in-vehicle - a ʻaʻohe o lākou e hōʻike i ka maikaʻi o ka bioavailability waha. ʻO ia ke kiko kūpono e lawe ai i nā kūkākūkā kūloko.
No ke aha i hiki ʻole ai i ke kaʻina hoʻokahi ke hoʻoholo i ke kūpono o ka waha
A 2026 Hōʻike nā Frontiers i nā pale peptide waha ʻōlelo paʻa i ka hihia physicochemical: ʻano nui nā peptides, polar a kau ʻia, ka mea e hoʻopuka ai i ka haʻahaʻa haʻahaʻa ma o ka papa mucus a me ka epithelium lalo; Hiki lākou i nā protease ʻōpū a me ka ʻōpū; e hui pū lākou; a ʻaʻole paʻa pinepine lākou i nā ala e paʻakikī ai ka hoʻomohala ʻana i ke ʻano o ka dosage paʻa paʻa. Hoʻokomo ka loiloi i ka bioavailability waha no ka hapa nui o nā pūhui ma lalo 1%.
ʻO kēlā mau waiwai he mau ʻoiaʻiʻo pae kaʻina, a hoolaha lakou. Hoʻoholo ka uku a me ka hāʻawi ʻana i ka hoʻoili ʻana inā e hele ka peptide i kahi pūnaewele mucus i hoʻopiʻi maikaʻi ʻia a hoʻopaʻa ʻia paha. Hoʻonohonoho ka Hydrophobicity i ka pili o ka membrane a me ka pilikia o ka hui ʻana iā ʻoe iho i nā manaʻo e pili ana i ka formulation.. ʻO nā kumu hoʻonaʻauao-protease - nā wahi dibasic no nā enzymes like trypsin, nā koena ʻala no ka chymotrypsin, Nā koena N-terminal no nā aminopeptidases - e hoʻoholo i nā enzyme luminal e hoʻouka mua a ma kahi o ka hoʻololi hoʻololi e loaʻa ai ka nui.. Hoʻoholo ʻia ka propensity agregation inā hiki ke kiʻi ʻia ka ʻike e pono ai no ka dosing i ke kaʻa i koho ʻia.
ʻO ia ke kumu ʻaʻole hiki i kahi palapala hoʻomaʻemaʻe o ka nānā ʻana ke hoʻoholo i ka hiki waha. ʻO ka maʻemaʻe HPLC kahi pākēneka wahi pili; haʻi ʻo ia iā ʻoe i ka nui o ka mea e hoʻopili ai i ka UV ke kiʻekiʻe nui. ʻAʻole ia e haʻi iā ʻoe i ke ʻano counterion, ka wai i koe, ka waihona peptide net, a i ʻole ke ʻano o ka mole ke hui ʻo ia i ka ʻakika ʻōpū, nā paʻakai bile a me nā enzyme pancreatic i ke kaʻina. Hiki i kahi peptide 98% maʻemaʻe a hāʻule mau i ka pale mua.
Hōʻike pū ka loiloi i ke kumu ʻaʻole i hoʻopaʻa ʻia ke kahua ʻoiai ʻo sub-1% bioavailability. Nā hoʻololi hoʻololi e hoʻonui i ka mana, ʻO ke kūpaʻa metabolic a me ka hapalua o ke ola e ʻae i ka hopena therapeutic ma ka haʻahaʻa haʻahaʻa helu hoʻokahi. ʻO ka semaglutide waha ka laʻana i hoʻokumu ʻia; Hōʻike pū ka loiloi i ka macrocyclic PCSK9 inhibitor enlicitide a me ka IL-23 receptor antagonist icotrokinra ma ke ʻano he hopena hope a i ʻole nā hopena maʻi., a me Chugai's cyclic peptide Luna18, i hiki i ka 21% -47% oral bioavailability ma preclinical models. Ua neʻe ka paepae no ka mea ua hana ʻia ka mole no ia - a ʻo kēlā ʻenekinia kahi hoʻoholo synthesis.
Pono e hoʻopaʻa ʻia ka pale, ʻAʻole hoʻokahi
Pono e heluhelu pono ʻia ka haʻawina ʻelua papa GLP-1 no ka mea e hōʻike ana i ka hoʻopaʻa ʻia ʻana o nā papa ma mua o ka ʻike ʻole ʻia..
Exenatide i koe ma hope 60 min i loko o ka α-chymotrypsin (7.50 µg/mL, wela lumi, Heluhelu HPLC). Ua hoʻohaʻahaʻa loa ʻia ka exenatide unformulated i loko o nā minuke; ʻO ka lua hydrophobic i loko o ka hoʻokumu ʻana i ka lipid-based i mālama ʻia 80%. ʻO ka ʻokoʻa ma waena o ka sodium caprate (C10) a ʻaʻole koʻikoʻi nā lima no-C10. ʻO ka pale proteolysis in vitro wale nō - ʻaʻole permeability, absorption a bioavailability paha. Puna: Dumont et al., Imua. Laau Laau Deliv. 2026;6:1770094.
Ma ka pae mole, ua hoʻololi nā mea kākau i ka exenatide acetate i ka lua hydrophobic ion. Ua neʻe ʻia nā ana P log mai −2.9 ± 0.3 no ka acetate i 0.1 ± 0.2 a 0.9 ± 0.2 no nā hui ion SLS a me DOC ma a 1:4 ratio molar, a ua lawe ʻia ka lua DOC i mua. He hoʻoholo kemika kēlā e hoʻololi i ke ʻano hoʻokaʻawale ʻana o ka mole - ke ʻano o ke koho i loko o ka hana synthesis a me ke koho paʻakai., ʻaʻole i loko o kahi hui hoʻonohonoho e hana ana mai kahi API paʻa.
Ma ka pae hoʻokumu, ua hoʻoukaʻia ka HIP i loko o ka hoʻokumu lipid-based me nā mea hoʻonui i ka permeation. ʻO ka pae lipid hana ʻelua mau hana: mālama ia i ka peptide mai ka hoʻopili pololei ʻana me nā protease ʻōpū, a hoʻohui pū i ka peptide me ka mea hoʻonui permeation ma ka ʻili epithelial. ʻO ka hōʻike pale ʻike ʻo ia ka hui ʻana i kahi i pau ʻole ai ka nui o nā ʻano mea hoʻohana waha - inā hoʻokuʻu ʻia ma ka ʻāpana hewa., a i ʻole ka hoʻoheheʻe ʻana, a i ʻole ka mea hoʻonui e hoʻokaʻawale mai ka API, hāʻule ka unuhi ʻana.
Ma ka pae ʻano dosage, Hāʻawi ka capsule enteric maʻamau i ka pale o ka ʻōpū a pale i ka dilution premature o ka pae lipid i ka wai ʻōpū, ka mea e hoʻoneʻe i ka peptide mai kona wahi palekana. Hoʻonohonoho ʻia ka hoʻokuʻu ʻana o ka peptide a me ka mea hoʻonui i ka wahi hoʻoheheʻe o ka ʻōpū.
ʻO ka ʻike aʻoaʻo loa i ka pepa he ʻike hoʻolālā e ʻike wale ʻia ke aʻo pū ʻia ka peptide a me ke kaʻa.: ʻO ke kūpaʻa wā pōkole i hōʻike i ka hoʻohaʻahaʻa ʻana i ka hoʻokumu ʻana, me ka hoʻokumu ʻana i ka haumia kiʻekiʻe no ka EXE-HIP solubilized ma mua o ka EXE acetate i hoʻokuʻu ʻia, ʻoi aku ma kahi mahana wela. ʻO ke kūlana kino o ka API - hoʻonā me ka hoʻokuʻu ʻia - ua hoʻololi i ke ala hoʻohaʻahaʻa. ʻO kahi hui i hōʻike ʻia i ka pauka lyophilized wale nō e poina i kēia, a ua ʻike ʻia ma hope, ma kahi ʻoi aku ka pipiʻi.
Hoʻopaʻa pū nā mea kākau i kahi pilikia o ka oxidation i hoʻokumu ʻia ma ke kaʻina: methionine 14 a me ka tryptophan 25 hiki ke ho'ohāhā i loko o nā matrices lipid i loa'a nā peroxides, nā aldehydes a i ʻole nā ion metala. ʻAʻole hiki i kā lākou ʻano voltammetry cyclic ke ʻike i ka antioxidant pono loa, No laila, ʻōlelo lākou i nā mea hoʻohui lipid hou a me ka mālama ʻana i ka mālamalama a me ka ʻike oxygen. He laʻana koʻikoʻi kēlā o kahi hiʻohiʻona kaʻina e alakaʻi ana i ka hoʻokumu ʻana a me ke koi ʻana.
Hoʻoholo ʻia ʻo Terminal-Ileum: No ke aha he mea nui ka Pae a me ka Transit
ʻO ka ileum distal kahi pahuhopu koʻikoʻi no nā kumu like ʻole ma ke ʻano. He wahi absorption ia no kekahi mau lāʻau lapaʻau a me nā ʻano hana hou, me nā lāʻau lapaʻau olaola a me ka nucleic acid-based therapy, a me ka hāʻawi ʻia ʻana ma laila hiki ke hoʻonui i ka pono kūloko me ka hōʻemi ʻana i ka ʻike pūnaewele a me nā hopena i waho, e like me ka Hōʻuluʻulu Capsugel memo. Lawe pū ʻo ia i ka manaʻo kiʻekiʻe loa o nā pā a Peyer, He mea nui ia no ka huli ʻana i ka immune mucosal, e like me ka Nefecon imaging study hōʻike.
ʻO ka paʻi ʻana me ka hilinaʻi ka mea paʻakikī. Loaʻa ka ʻāina i kahi kaiapuni physiological ikaika a me kahi manawa transit pōkole, a ua ʻike ka hōʻuluʻulu manaʻo i ka hoʻokuʻu ʻia ʻana ma laila ʻo ia kekahi o nā pilikia nui i koe i ka lawe ʻana i ka lāʻau lapaʻau waha.
ʻO ka papa kuhikuhi maikaʻi loa i loaʻa mai kahi noiʻi kiʻi kanaka o ka capsule Nefecon, kahi hoʻopuka budesonide i hoʻokuʻu ʻia i hoʻokuʻu ʻia i ʻae ʻia no ka nephropathy IgA mua e hana ana i ka hoʻonui ʻana i ka galactose-deficient IgA1 ma nā pā o Peyer.. Ua hoʻohana ke aʻo ʻana i nā capsule hoʻāʻo e hana hou ana i ka hana hoʻokuʻu lohi o Nefecon, me ka caffeine i hoailona no ka wehe ana o ka capsule (ʻike koke ʻia i loko o ka saliva ma hope o ka hoʻokuʻu ʻana) a me ke kiʻi hoʻonaʻauao magnetic me ka hao ʻeleʻele ʻeleʻele e ʻimi ai i ka capsule a nānā i ka hoʻopuehu ʻana. Ua hōʻoia ʻia ka dissolution in vitro ua kūlike nā capsules hoʻāʻo me nā ʻano hoʻokuʻu o Nefecon. In 10 o 12 nā mea manawaleʻa i wehe ʻia ka capsule ma ka ʻaoʻao distal; ma nā ʻelua ʻē aʻe ua wehe ʻia ma mua o ka hui ʻana o ka ileocecal. Hōʻike nā mea kākau i kēia i mea maikaʻi e kūʻē i ka loli kiʻekiʻe i hōʻike ʻia ma nā haʻawina kiʻi paʻi ʻē aʻe o nā hoʻopuka hoʻokuʻu lohi e kuhikuhi ana i ka ʻōpū..
ʻO kēlā hopena he mahele, aole he kiko. He ʻumi o ʻumikūmālua ka hopena ikaika no ke kahua, a ʻo ia hoʻi, ʻaʻole i kuhikuhi ʻia kahi kikoʻī hoʻokuʻu i kākau ʻia e kūʻē i ka manawa nominal hoʻokahi. Inā ʻo kāu wahi i hoʻopaʻa ʻia ʻo ka ileum distal, Pono ka wehewehe ʻana e wehewehe i ka hana ʻae ʻia ma waena o kahi kaʻahele transit - me ka huelo o nā kumuhana i hōʻea lohi - a pono e hiki i ka panel assay ke hoʻokaʻawale i kahi capsule i wehe ʻia ma kahi hewa mai kahi peptide i hoʻohaʻahaʻa ʻia ma hope o ka wehe ʻana i ka mea kūpono.. E nānā pū i ka laulā: ʻO kēia kahi haʻawina hoʻonaʻauao 12 mau manawaleʻa o kahi hana budesonide, a ʻaʻole pono e hoʻoneʻe ʻia kāna mau helu i kahi papahana peptide e like me ka helu kūleʻa i manaʻo ʻia.
ʻO ka Lepili kekahi ʻāpana o ka hoʻokolohua
Pono kēlā me kēia hoʻokolohua hoʻoili a biodistribution i kahi peptide i kahi ala e ʻike ai, a ʻo ke ʻano āu e ʻike ai he hoʻololi kemika. ʻO nā koho maʻamau he mau kala fluorescent, nā leka uila e like me 3H, 14C a i ole 125I, nā isotopes paʻa, biotin, a me nā hōʻailona kemika like ʻole. Hāʻawi kēlā me kēia i kahi ʻano hoʻopiʻi ʻokoʻa: Hiki i ka fluorophore nui ke hoʻomalu i ka waiwai o ka peptide liʻiliʻi, kahi radiolabel e pani i ka atom, Hoʻohui ka biotin i kahi ligand hydrophobic-bicyclic nui e hiki ke hoʻopaʻa i nā protein e like me streptavidin i nā wahi i manaʻo ʻole ʻia..
ʻO ka microfluidic intestinal-barrier hana haʻi pololei i ka pilikia. No ka mea, pono ka heluhelu ʻana i ka microscopy i kahi mea hoʻolaha fluorescent, a no ka mea hiki i ka hoʻololi ke hoʻololi i ke ʻano o ka lawe ʻana o nā mea olaola - ʻoi aku hoʻi no nā peptides liʻiliʻi - hoʻopaʻapaʻa nā mea kākau he mea koʻikoʻi ke koho ʻana i nā kala e hoʻopilikia liʻiliʻi i nā waiwai physicochemical o ka biologic, no ka laʻana fluorophores i hōʻike ʻia he liʻiliʻi ka makemake no ka launa pū ʻana o ka membrane lipid. Haʻi lākou i ka hana i hoʻololi nui ʻia ka lepili fluorophore o kahi peptide e komo ana i ke kelepona i ke ʻano a me ke kiʻekiʻe o ka pilina biomembrane..
He mea ana ia me ka nui like me ka hopena e ana ana. ʻO kahi peptide i hoʻopaʻa inoa ʻia e hoʻopaʻa i nā membrane ʻoi aku ka maikaʻi ma mua o kona makua e ʻoi aku ka permeable i loko o kahi hoʻohālike cell a emi ʻole ka loaʻa ʻana i kahi hōʻike luminal stability., a ʻaʻohe hopena e hōʻike ana i ka molele i hōʻailona ʻole ʻia.
ʻO ke kānāwai kūpono: koho i ka lepili e hoʻopilikia iki i ka waiwai āu e ana, a laila e hōʻoia i ka hana like ʻana o nā ʻano mea i hōʻailona ʻia a ʻaʻole i hoʻopaʻa ʻia i ka hoʻāʻo ma mua o ka hilinaʻi ʻana i ka heluhelu ʻana.. No kahi haʻawina permeability, ʻo ia hoʻi ka hoʻohālikelike ʻana i ka lawe ʻana o ka peptide i hoʻopaʻa ʻia me ka peptide ʻole i hoʻopaʻa inoa ʻia ma ke kumu hoʻohālike. No kahi haʻawina kūpaʻa, ʻo ia hoʻi ka hōʻoia ʻana i ka lepili ʻaʻole e hoʻololi i ka ʻaoʻao degradation. No ka haʻawina biodistribution, ʻo ia ke ʻano o ka helu ʻana i ka orthogonal - LC-MS/MS o ka peptide i hoʻopaʻa ʻole ʻia, no ka laʻana - kū'ē i ka hōʻailona kiʻi. Inā ʻokoʻa ka ʻano lepili a me ka lepili ʻole, ʻo ka lepili ka hoʻokolohua, ʻaʻole ka peptide.
Heluhelu i ka ʻikepili: ʻO wai ka Assay e pane i ka nīnau
Hoʻopuka ka hoʻokolohua peptide waha i kahi hōʻailona, ʻaʻole he hōʻailona. Hōʻike ka papa ma lalo i nā hōʻailona maʻamau i nā hoʻokolohua hiki ke hoʻokaʻawale i ko lākou kumu. He kahua hoʻomaka, ʻaʻole he lāʻau hoʻoholo i hōʻoia ʻia; no kāu huahana nā ʻano kikoʻī a me nā pae hoʻohālikelike a pono e ʻae ʻia I Q2(R2) a me kāu pae hoʻomohala ponoʻī.
|
hōʻailona |
ʻO nā kumu paha |
ʻO nā hoʻokolohua e hoʻokae |
|---|---|---|
|
Hoʻolaha haʻahaʻa i ka plasma ma hope o ka hoʻopaʻa waha |
Hoʻokuʻu ʻia ka capsule maikaʻi ʻole; ka hoʻohaʻahaʻa ʻana o ka peptide i loko o ka ʻōpū a i ʻole ka wai ʻōpū; haʻahaʻa epithelial permeability; adsorption i ka capsule a paipu paha; ka hui ʻana |
Hoʻoheheʻe ʻelua ʻāpana me ka laʻana kikoʻī kikoʻī; hoʻohālikelike ʻia ka ʻōpū a me ka ʻōpū o ka wai me ka ʻike LC-MS o nā ʻāpana; ʻike ʻia ka permeability i loko o kahi hoʻohālike epithelial me ka mucus a me ka ʻole; ke kaulike nui ma ka capsule a me ka mea hoʻohana; hoʻopuehu māmā a i ʻole chromatography hoʻokaʻawale nui no ka hōʻuluʻulu ʻana |
|
Hoʻokumu i ka haumia kiʻekiʻe i ka hoʻokumu ʻana |
Hoʻoemi kemika (oxidation, hydrolysis, deamidation); ka pilina peptide-excipient; nā hopena kūlana kino (hoʻonā vs. hoʻopaneʻe) |
Hoʻohaʻahaʻa ikaika ʻia me ka ʻike ʻana i nā ʻāpana e MS/MS; hoʻopaʻa haʻawina hoʻokō i ke kūlana mālama; ka hoʻohālikelike o ka API i hoʻoheheʻe ʻia ma lalo o nā kūlana like |
|
Wehe ka Capsule ma ka ʻāpana hewa |
ʻO ka hui pū ʻana a i ʻole ka mānoanoa uhi; lāʻau hoʻoponopono; ʻokoʻa kaʻahele |
In vivo imaging me kahi hōʻailona kūlana; hoʻokuʻu in vitro i loko o kahi kumu hoʻoheheʻe multi-compartment; ke aʻo ʻana o nā ʻāpana no ka mālama ʻana i ka mahana a me ka haʻahaʻa |
|
Loaʻa ka hōʻailona akā ʻaʻole ka hopena |
Lepili mea hana; keakea hoao; ʻAʻole hana ka peptide ma hope o ka hōʻailona ʻana |
Ka helu helu ʻole ʻia (LC-MS/MS); ka ho'āʻo hana orthogonal ma luna o nā mea i hoʻopaʻa ʻia a me ka lepili ʻole |
|
ʻO ka hoʻololi ʻana o ka hui ʻana i ka hana hāʻawi |
ʻO nā ʻokoʻa ʻokoʻa o ka ʻokoʻa ʻokoʻa o ka peptide ʻokoʻa; koena No ka hale hana peptides wai; mokuʻāina ʻāhui; nui ʻāpana |
ʻO ka maʻiʻo e kūʻē i ka ion chromatography; net peptide e CHN a i ʻole ka helu helu amino acid; ʻO Karl Fischer ka wai; puunaue ka nui o na mea liilii |
He mea nui ka hua'ōlelo analytical maanei. ʻO ka hoʻomaʻemaʻe kahi pākēneka wahi pili e HPLC a ʻaʻole ʻōlelo e pili ana i ka nui o ka peptide mass. ʻO ka Identity kahi hōʻoia hoʻonohonoho orthogonal - mass spectrometry me kahi ʻenehana lua. Maʻiʻo, aiʻole ka peptide net, he helu kaulike nui e helu ana i ke ku'e, wai a me nā mea hoʻoheheʻe koena. Peptides pūnaewele ʻO ke kūpaʻa kahi hoʻolālā haʻawina me nā kūlana i wehewehe ʻia a me nā manawa, aole ana hookahi. ʻO ke kūpono o ka Assay e pili ana i ke ʻano, matrix a me nā mana. ʻAʻole hiki i ka helu hoʻomaʻemaʻe HPLC hoʻokahi ke hoʻoholo i ka hāʻule ʻole o ka lawe ʻana, a ʻo ka mālama ʻana iā ia me he mea lā ʻo ia kekahi o nā ala maʻamau e hoʻolilo ai ka papahana i ka hapaha i ka hahai ʻana i ka loli hewa.
I Q2(R2), hāpai ʻia 1 Nowemapa 2023, ʻo ia ka heleuma kūpono no ka ʻaoʻao analytical. ʻO kāna ʻāpana kikoʻī a koho i nā ʻikepili hōʻike - chromatograms, electropherograms, spectra - me nā mea pili i hōʻailona ʻia, a no ka noiʻi ʻana i ka hoʻokae kūpono ma kahi pae kūpono, e like me ka hoʻonā ʻana o nā ʻāpana pili-eluting ʻelua i kahi kaʻawale koʻikoʻi. ʻO ia ke ʻano maʻamau e pono ai ke ʻano o ka lawe ʻana: hiki iā ia ke ʻike i ka huahana degradation āu e ʻimi nei, ʻaʻole wale ka piko nui.
Mai ka ʻikepili Synthesis a i nā hoʻoholo hoʻouna
Maikaʻi ka hoʻoponopono hou ʻana i ka wā i hoʻonohonoho pono ʻia ai nā pale. ʻO ka palapala hōʻoia, ka chromatogram, ke ano kue, ka solubility a me ka ʻikepili hui, a ʻaʻole hoʻokuʻu ʻia nā manawa paʻa i nā pepa e pili ana i kahi hoʻolaha synthesis. ʻO lākou nā mea hoʻokomo e kāohi i kēlā me kēia koho i lalo, a pono e kuhikuhi ʻia me ke ala lawe ʻana mai ka hoʻomaka ʻana.
E holo ana kahi kaʻina hana e like me kēia: Kūʻai i nā Peptides
-
E wehewehe i ka paena GI a me ka puka makani hoʻokuʻu. ʻIleum kūwaho, ʻōpū liʻiliʻi kokoke, hoʻololi paha ka ʻōpū i ka pūpū, ka uhi ʻana, a me nā manaʻo transit ua kākau ʻia ke kikoʻī.
-
E kiʻi i nā koi kūpaʻa a me ka permeability mai ke kaʻina. E ʻike i nā kumu protease-susceptibility, nā koena hoʻohāhā, ʻāpana hoʻohuihui, a me ka palapala hoʻoili a me ka hydrophobicity. Hoʻonohonoho kēia i ka kemika stabilization haʻahaʻa a me ka hoʻolālā permeability.
-
E koho i ke kemika hoʻopaʻa. Nā koena non-canonical, cyclization, N-methylation, lipidation, a i ʻole ka hoʻopaʻa ʻana i nā ion - e kamaʻilio kēlā me kēia i kahi kuleana kikoʻī i ʻike ʻia ma ka pae 2, a he hoʻoholo synthesis kēlā me kēia me kona mau hopena analytical. Hale Hana Peptides Lepili Isotope
-
E koho i ka hana. Māhele lipid, mea hoʻonui i ke komo ʻana, mea hoʻopaneʻe protease, pH modulator. E hōʻoia i ke kūlana kino o ka peptide i loko o kēlā kaʻa a me kona kūlike me nā mea kōkua i ke kūlana mālama i manaʻo ʻia..
-
E koho i ka ʻōnaehana hoʻokuʻu. Puʻupuʻu pūpū, ka uhi ʻana, a i ʻole ka papa hana ʻelua, me ka palapala hoʻokuʻu i kākau ʻia e kūʻē i ka puʻunaue transit ma mua o ka manawa koho.
-
E wehewehe i ka papa hoʻāʻo e hōʻoia i kēlā me kēia kaʻina. Hoʻoheheʻe me ka laʻana kikoʻī kikoʻī, HPLC hōʻike kūpaʻa, hōʻoia ʻike orthogonal, maʻiʻo a me ka counterion, a me ka hoʻohālikelike hoʻohālikelike ʻia me ka lepili ʻole no nā kiʻi a i ʻole ka heluhelu ʻana i ka lawe ʻana.
ʻO ka hoʻopaʻi koʻikoʻi ka ʻike ʻana i ka wā e hoʻololi ai ka hoʻololi ʻana i kahi hoʻoholo hoʻoholo mua. E hoʻololi i ke koena e hoʻomaikaʻi i ka mana a hiki iā ʻoe ke hoʻololi i ka uku, ka houluulu ana, ka lāʻau P, a i ʻole ke kuleana o ka oxidation - a me ka pālua ion, ke kaʻa lipid, a pono paha ke kii hou ia ka moolelo hoopuka capsule. ʻO kahi mana kaʻina i hoʻololi ʻole ʻia ke kumu maʻamau o kahi hopena hoʻohua ʻaʻole hiki ke hana hou ʻia.. E mālama i ke kaʻina a me kona mōʻaukala hoʻololi ʻana ma ke ʻano he moʻolelo hiki ʻole ke hoʻololi, a hoʻomaka hou i ka hana hoʻoponopono i hoʻopili ʻia i kēlā me kēia manawa e loli ai kēlā moʻolelo.
ʻO ia hoʻi kahi i loaʻa ai i ka haʻawina GLP-1 ʻelua mau wahi ma ke ʻano he kumu hoʻohālike. ʻAʻole hāʻawi nā mea kākau i kahi API i hoʻopau ʻia i kahi hui hoʻonohonoho. Ua hoʻololi lākou i ke ʻano paʻakai e hoʻololi i ka ʻāpana, ua aʻo i ke kūlana kino o ke kaʻa, ʻike ʻia nā ʻae ʻana o ka oxidation mai ke kaʻina, a kūkulu i ka capsule a puni nā pono o ka hoʻomākaukau ʻana. ʻO ka synthesis a me ka lawe ʻana i hoʻokahi papahana.
Kahi e kūpono ai nā hoʻololi MOL
Kāhea ʻia ka framework ma luna i kahi hoa upstream e hiki ke hana i ka peptide a me ka ʻike kikoʻī me ke ala lawe i ʻike ʻia.. MOL Changes he hui noiʻi a me ka hoʻomohala peptide e ʻōlelo ana e hāʻawi ana i nā ala noiʻi kūpono no ka holomua o ka ʻepekema peptide., a me kāna mau mana i hōʻike ʻia i palapala ʻia ma nā ʻanuʻu mua o kēlā kaʻina.
Ma ka synthesis, ʻōlelo ka ʻoihana ua haku ʻo ia i ka pae paʻa, ʻāpana wai, hui pū wai-paʻa, ʻO nā ʻano hana fermentation inverse solid-phase a me microbial, me nā kaʻina hana maʻamau a hiki i 200 nā amino acids a me ka unahi mai milligrams a hiki i kilokani. Ma ka hoʻololi, papa inoa ia i ka cyclization, kāʻili ʻana, glycosylation, phosphorylation, PEGylation, lipidation, hōʻailona isotope, ka hōʻailona fluorescent a me ka biotinylation ma waena o nā mea ʻoi aku 300 hoʻololi i nā hui - nā kemika i ʻike ʻia ma nā ʻanuʻu 2 a 3 maluna. Ma ka maikaʻi, ʻōlelo ʻia e mālama ʻia ka hana ʻana ma kahi papa i wehewehe ʻia e ka mea hoʻolako 100 lumi hoʻomaʻemaʻe mai ka pae hoʻokolohua mua ma ka hoʻopili ʻana, me ka nānā ʻana i ka sterilization, kaomi ea, haʻahaʻa, ka wela a me ka lepo, a ua uhi ʻo QC i ka HPLC, MS, ka maemae, maʻiʻo, endotoxin, sterility, pH a me ka makū me ka ʻikepili kikoʻī pūʻulu.
ʻElua o ia mau mōhai pili pono i nā pilikia ana i kūkākūkā mua ʻia. ʻO nā lawelawe hōʻailona fluorescent a me isotope nā hoʻololi like e hiki ke hoʻopilikia i ka ʻano halihali o kahi peptide.; ʻO kahi hoa lepili e hōʻike ana i ka moʻolelo analytical o nā ʻano i kapa ʻia ma ka ʻaoʻao o ka makua e hāʻawi iā ʻoe i ka ʻikepili e nānā i ka hoʻohālikelike.. ʻO ke koho Counterion kahi lever pili - ua papa inoa ka hui iā TFA ma ke ʻano he paʻamau, me ka acetate, chloride a i ʻole ammonium paʻakai hoʻololi i loaʻa - akā, ke hoʻololi ka log P i ka ʻelua papa haʻawina, mai −2.9 ± 0.3 no ka exenatide acetate i 0.9 ± 0.2 no kāna hui ion DOC, i hele mai mai ka hui ʻana o ka ion hydrophobic, ʻaʻole mai kēlā ʻano hoʻololi paʻakai.
E maopopo e pili ana i ka laulā: Hōʻike ʻo MOL Changes i kēia me kāna synthesis ponoʻī, hoʻololi, pālākiō a me ka mana QC. ʻAʻole ia e hana i ka ʻenehana capsule, nā noiʻi kiʻi a i ʻole nā hana lapaʻau i wehewehe ʻia ma nā kumu ma luna, ʻaʻohe mea ʻē aʻe ma ʻaneʻi. ʻOi aku ka liiki a ʻoi aku ka maikaʻi o ka pilina - ʻo nā koho synthesis a me nā hiʻohiʻona e hoʻoholo ai inā loaʻa kahi papahana hoʻouna i lalo i kahi hoʻomaka kūpono e hana ʻia ma kēia pae., a ʻoi aku ka maikaʻi o ka hana ʻana me ke ala hoʻouna i ʻōlelo ʻia.
Hōʻike: ʻO MOL Changes kahi mea kūʻai aku i ka peptide synthesis a me ka hoʻololi ʻana a loaʻa iā ia kahi hoihoi pāʻoihana i ka maikaʻi a me nā kūlana palapala i kūkākūkā ʻia ma kēia ʻatikala..
Nā Kuhikuhi a me nā memo kiʻi
Ua kiʻi ʻia nā kumu ma 27 ʻOkakopa 2026. Hōʻike ʻia nā kiʻi a me nā hopena ma ke ʻano o ka haʻawina i haʻi ʻia a ʻaʻole pono e hoʻonui ʻia i nā molekala ʻē aʻe., formulations a i ʻole ka poʻe maʻi me ka hōʻoia ʻole.
-
Capsugel® Enprotect® capsules, ʻaoʻao huahana, Lonza/Capsugel: https://www.capsugel.com/pharmaceutical-solutions/hard-empty-capsules/enprotect-capsules. Hōʻike ʻia ka pale ʻana i ka wai a hiki i ka pH 6.0; ʻaʻohe uhi hoʻopiha piha.
-
ʻO ka hōʻuluʻulu ʻike-waena Capsugel o Millet E, Vandenbroucke SST, O’Shea JP, ʻO Griffin BT, ʻO Jannin V. Hoʻolālā a kaʻina hana loiloi o nā ʻōnaehana capsule bilayer no ka hāʻawi ʻana i ka lāʻau lapaʻau ileal. ʻEpelika Journal of Pharmaceutical Sciences 2026;224:107601. doi:10.1016/j.ejps.2026.107601: https://www.capsugel.com/knowledge-center/pharma/capsules/targeted-ileal-delivery-Enprotect-capsules. Hoʻoponopono a me ke kaʻina hana hoʻopaʻa haʻawina; ʻaʻohe in vivo absorption i hōʻike ʻia ma ka hōʻuluʻulu.
-
Dumont et al. ʻO kahi hoʻolālā palekana ʻelua-papa no ka hāʻawi waha o GLP-1 peptides: ʻO ka hoʻokumu ʻana o ka lipid i hui pū ʻia me nā capsules enteric. Nā palena i ka lawe ʻana i ka lāʻau lapaʻau 2026: https://www.frontiersin.org/articles/10.3389/fddev.2026.1770094/full. In vitro hōʻoia o ka manaʻo; in vivo PK/PD a me ka paʻa lōʻihi i ʻike ʻia e nā mea kākau ma ke ʻano he hana e hiki mai ana.
-
ʻO Khalid et al. ʻO ka nānā ʻana i nā pale lawe peptide waha. Nā palena i ka lawe ʻana i ka lāʻau lapaʻau 2026: https://www.frontiersin.org/journals/drug-delivery/articles/10.3389/fddev.2026.1809842/full. ʻO ka helu bioavailability sub-1% kahi ʻōlelo pae loiloi e pili ana i ka hapa nui o nā pūhui, ʻaʻole he waiwai āpau; ʻO ka helu 21%–47% no Luna18 he preclinical.
-
Nefecon distal-ileum imaging study, PubMed abstract: https://pubmed.ncbi.nlm.nih.gov/38723178/. He ʻumikūmālua mau mea manawaleʻa; Ua wehe ʻia ka capsule ma ka ʻaoʻao o ka ileum 10 a hala wale aku i ka hui ileocecal ma 2.
-
Weller et al. ʻO ke kumu hoʻohālike epithelial ʻākea microfluidic intestinal. Nā palena i ka Bioengineering a me Biotechnology 2022;965200: https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.965200/full. Ua ʻike ʻia ka pilikia o ka fluorophore no nā peptides liʻiliʻi.
-
Palaunu, Whitehead & Mitragotri. Nā mea no ka lawe waha o nā protein a me nā peptides. Nā Mea Hana Nānā Natura 5:127–148: https://www.nature.com/articles/s41578-019-0156-6. Ka nānā 'ana i nā pale physiological.
-
I Q2(R2), Hōʻoiaʻiʻo o nā Kaʻina Hana Analytical, ʻae ʻia ka mana hope 1 Nowemapa 2023: https://database.ich.org/sites/default/files/ICH_Q2(R2)_Guideline_2023_1130.pdf.
-
I Q1A(R2), ʻO ka hoʻāʻo ʻana i ke kūpaʻa o nā mea lāʻau a me nā huahana hou, ma o FDA: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products.
-
MOL Changes: kahua hui, hana peptide maʻamau, hoʻāʻo peptide. ʻO nā mana i hōʻike ʻia e ka ʻoihana wale nō.
